Provided by Tiger Trade Technology Pte. Ltd.

Altimmune, Inc.

4.31
-0.1500-3.36%
Post-market: 4.350.0400+0.93%19:59 EST
Volume:3.02M
Turnover:13.10M
Market Cap:539.75M
PE:-4.08
High:4.47
Open:4.40
Low:4.29
Close:4.46
52wk High:7.73
52wk Low:2.90
Shares:125.23M
Float Shares:124.00M
Volume Ratio:1.06
T/O Rate:2.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0561
EPS(LYR):-1.3388
ROE:-52.61%
ROA:-30.87%
PB:2.91
PE(LYR):-3.22

Loading ...

Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday

Benzinga_recent_news
·
Jan 05

Shares of Altimmune Rise 21.4% After US FDA's 'Breakthrough' Tag for Liver Disease Drug

THOMSON REUTERS
·
Jan 05

BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Liberty Energy, Fortive

Reuters
·
Jan 05

BUZZ-Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug

Reuters
·
Jan 05

Altimmune Earns FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Reuters
·
Jan 05

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in Mash

THOMSON REUTERS
·
Jan 05

Altimmune Director Diane Jorkasky Acquires Common Shares

Reuters
·
Dec 30, 2025

Insider Buying: Altimmune Independent Chairman Bought US$52k Of Shares

Simply Wall St.
·
Dec 28, 2025

Altimmune Director Jerome Benedict Durso Reports Acquisition of Common Shares

Reuters
·
Dec 23, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Intuitive Machines, Palo Alto Networks, Redwire

Reuters
·
Dec 19, 2025

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Reuters
·
Dec 19, 2025

Altimmune Shares Climb 6.9% Premarket After Positive Trial Data

THOMSON REUTERS
·
Dec 19, 2025

Altimmune Reports Positive 48-Week Phase 2b Results for Pemvidutide in MASH Trial

Reuters
·
Dec 19, 2025

Altimmune Inc - Pemvidutide 1.8 Mg Dose Achieves 7.5% Weight Loss

THOMSON REUTERS
·
Dec 19, 2025

Altimmune Announces That Pemvidutide Achieved Key Measures of Success at 48 Weeks in Impact Phase 2B Mash Trial

THOMSON REUTERS
·
Dec 19, 2025

FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up

Reuters
·
Dec 12, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa Resources

Reuters
·
Dec 02, 2025

Altimmune CEO Vipin Garg to Step Down

MT Newswires Live
·
Dec 01, 2025

BUZZ-Altimmune falls as CEO Vipin Garg to step down

Reuters
·
Dec 01, 2025

BRIEF-Altimmune Announces CEO Transition, Succession Plan

Reuters
·
Dec 01, 2025